

THIS PRESS RELEASE IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO USA, AUSTRALIA, CANADA, JAPAN OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE ILLEGAL. SEE ALSO SECTION IMPORTANT INFORMATION BELOW.

InDex Pharmaceuticals publishes prospectus regarding initial public offering in connection with planned listing on Nasdaq First North Stockholm

September 13, 2016 - The board of directors of InDex Pharmaceuticals Holding AB (publ) (the "Company" or "InDex"), has prepared a prospectus in relation to the initial public offering of shares of class B to the general public in Sweden, Denmark and Norway as well as to professional investors in Sweden and internationally, decided by the board of directors and communicated through a press release earlier this day. The prospectus has today been approved by and registered with the Swedish Financial Supervisory Authority (Sw. Finansinspektionen).

The prospectus is available for download on the Company's website, www.indexpharma.com, on Aqurat's website, www.aqurat.se, Stockholm Corporate Finance's website, www.stockholmcorp.se, and will also be available on the Swedish Financial Supervisory Authority's website, www.fi.se.

Advisers

Stockholm Corporate Finance AB is the financial adviser and Setterwalls Advokatbyrå AB is the legal adviser to the Company in relation to the Offering. Aqurat Fondkommission AB acts as issuer agent in relation to the Offering. Nordnet Bank AB acts as Selling Agent in relation to the Offering.

About InDex Pharmaceuticals

InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The Company's foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis - a debilitating, chronic inflammation of the large intestine.

Cobitolimod is a new type of drug that can help patients with moderate to severe ulcerative colitis back to a normal life. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.

InDex Pharmaceuticals is based in Stockholm, Sweden. Among the main shareholders are SEB Venture Capital, Industrifonden and NeoMed Management. The Company's operations are mainly conducted through its subsidiary Index Pharmaceuticals AB. For more information, please visit www.indexpharma.com.

For further information:

Peter Zerhouni, CEO

Phone no.: +46 8 508 847 35

E-mail: peter.zerhouni@indexpharma.com

Miscellaneous

The board of directors of the Company will apply for listing of the Company's shares of class B on Nasdaq First North Stockholm and has appointed Redeye AB as Certified Adviser.

For further information, please visit www.indexpharma.com

IMPORTANT INFORMATION

This document has not been approved by any regulatory authority. The document is a press release and not a prospectus and investors should not subscribe for or purchase securities referred to in this document except on the basis of information contained in the prospectus that will be approved by the Swedish Financial Supervisory Authority and be kept available at the company's website. Distribution of this press release could in some jurisdictions be subject to restrictions according to law and recipients of this, or part of this, are required to inform themselves of, and comply with, such legal restrictions. Information in this press release should not constitute an offer to sell shares, or a solicitation of any offer to purchase shares, nor should any sale of the securities referred to herein be made, in any jurisdiction where such offer, solicitation of any offer to purchase, or sale would require preparing additional prospectus or other offering documents, or would not be lawful without registration or applicable exemptions from registering according to security acts in any such jurisdiction.

This press release neither constitutes, nor constitutes a part of, an offer or a solicitation of an offer to purchase or subscribe for securities in the United States. Securities referred to herein have not been, and will not be, registered in accordance with the American Securities Act of 1933 ("Securities Act"), and may not be offered or sold within the United States absent registration in accordance with the Securities Act, or an exemption therefrom. Securities referred to herein are not offered to the general public in the United States. Copies of this press release is not being made and may not be distributed or sent, in whole, or part, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or the United States or to any other jurisdiction where the distribution respectively the issuance of this press release would be unlawful.